litlas
Log inCreate account

Thomas Yau

Active 2006–2026

117
Papers
24,502
Citations
64
h-index
112
i10-index

Citations

Citations per year for Thomas Yau1977: 1 citations1978: 1 citations1984: 1 citations1991: 1 citations1994: 2 citations2007: 3 citations2008: 2 citations2009: 11 citations2010: 12 citations2011: 19 citations2012: 29 citations2013: 27 citations2014: 33 citations2015: 51 citations2016: 46 citations2017: 105 citations2018: 184 citations2019: 588 citations2020: 1,204 citations2021: 1,786 citations2022: 1,508 citations2023: 1,433 citations2024: 2,145 citations2025: 1,095 citations2026: 13 citations1979–1983: no citations, so these years are not shown1985–1990: no citations, so these years are not shown1992–1993: no citations, so these years are not shown1995–2006: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorChina: 2,521 citing papers, 23.3% of this breakdownUnited States: 1,953 citing papers, 18.1% of this breakdownItaly: 652 citing papers, 6% of this breakdownGermany: 518 citing papers, 4.8% of this breakdownJapan: 500 citing papers, 4.6% of this breakdownUnited Kingdom: 454 citing papers, 4.2% of this breakdownSpain: 380 citing papers, 3.5% of this breakdownFrance: 372 citing papers, 3.5% of this breakdownSouth Korea: 333 citing papers, 3.1% of this breakdownTaiwan: 304 citing papers, 2.8% of this breakdownHong Kong: 261 citing papers, 2.4% of this breakdownCanada: 249 citing papers, 2.3% of this breakdown
0%23.3%Other 21.4%

Institutions

Fields

  • Medicine75.3%
  • Biochemistry, Genetics and Molecular Biology15.8%
  • Immunology and Microbiology5.8%
  • Engineering1.1%
  • Neuroscience0.5%
  • Materials Science0.3%
  • Other1.2%

Topics

  • Hepatocellular Carcinoma Treatment and Prognosis11.6%
  • Cancer Immunotherapy and Biomarkers10.2%
  • Cholangiocarcinoma and Gallbladder Cancer Studies4.6%
  • Cancer Mechanisms and Therapy2.9%
  • Ferroptosis and cancer prognosis2.7%
  • Immunotherapy and Immune Responses2.6%
  • Other65.4%

Coauthors

All papers

Open in search
  1. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

    Authors: Ghassan K. Abou‐Alfa, George Lau, Masatoshi Kudo, Stephen L. Chan, Robin Kate Kelley, Junji Furuse, Wattana Sukeepaisarnjaroen, Yoon‐Koo Kang, Tu Van Dao, Enrico N. De Toni, Lorenza Rimassa, В. В. Бредер, Alexander Vasilyev, Alexandra Heurgué, Vincent C. Tam, Kabir Mody, Satheesh Chiradoni Thungappa, Yuriy Ostapenko, Thomas Yau, Sérgio Jobim Azevedo, Marı́a Varela, Ann‐Lii Cheng, Shukui Qin, Peter R. Galle, Sajid Ali, Michelle Marcovitz, Mallory Makowsky, Philip He, John F. Kurland, Alejandra Negro, Bruno Sangro - NEJM Evidence 2022 cited by 1,432

  2. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

    Authors: Anthony B. El-Khoueiry, Bruno Sangro, Thomas Yau, Todd S. Crocenzi, Masatoshi Kudo, Chiun Hsu, Tae‐You Kim, Su-Pin Choo, Jörg Trojan, Theodore H. Welling, Tim Meyer, Yoon‐Koo Kang, Winnie Yeo, Akhil Chopra, Jeffrey Anderson, Christine Dela Cruz, Lixin Lang, Jaclyn Neely, Hao Tang, Homa Dastani, Ignacio Melero - The Lancet 2017 cited by 4,315

  3. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

    Authors: Thomas Yau, Joong-Won Park, Richard S Finn, Ann-Lii Cheng, Philippe Mathurin, Julien Edeline, Masatoshi Kudo, James J Harding, Philippe Merle, Olivier Rosmorduc, Lucjan Wyrwicz, Eckart Schott, Su Pin Choo, Robin Kate Kelley, Wolfgang Sieghart, Eric Assenat, Renata Zaucha, Junji Furuse, Ghassan K Abou-Alfa, Anthony B El-Khoueiry, Ignacio Melero, Damir Begic, Gong Chen, Jaclyn Neely, Tami Wisniewski, Marina Tschaika, Bruno Sangro - The Lancet Oncology 2021 cited by 1,097

  4. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib

    Authors: Thomas Yau, Yoon‐Koo Kang, Tae‐You Kim, Anthony B. El-Khoueiry, Armando Santoro, Bruno Sangro, Ignacio Melero, Masatoshi Kudo, Ming-Mo Hou, Ana Matilla, Francesco Tovoli, Jennifer J. Knox, Aiwu Ruth He, Bassel F. El‐Rayes, Mirelis Acosta-Rivera, Ho-Yeong Lim, Jaclyn Neely, Yun Shen, Tami Wisniewski, Jeffrey Anderson, Chiun Hsu - JAMA Oncology 2020 cited by 1,212

  5. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: Robin Kate Kelley, Makoto Ueno, Changhoon Yoo, Richard S. Finn, Junji Furuse, Zhenggang Ren, Thomas Yau, Heinz‐Josef Klümpen, Stephen L. Chan, Masato Ozaka, Chris Verslype, Mohamed Bouattour, Joon Oh Park, Olga Barajas, Uwe Pelzer, Juan W. Valle, Li Yu, Usha Malhotra, Abby B. Siegel, Julien Edeline, Arndt Vogel, Mehmet Akce, Inmaculada Alés Díaz, Gustavo R. Alves, Sumitra Anand, Çağatay Arslan, Jamil Asselah, Eric Assénat, Eric Assenat, Li‐Yuan Bai, Yuxian Bai, Olga Barajas, Susan E. Bates, Stephen Begbie, Irit Ben‐Aharon, Nina Beri, Marie‐Luise Berres, Jean‐Frédéric Blanc, Ivan Borbath, Robert Bordonaro, Mohamed Bouattour, Giovanni Brandi, Adam M. Burgoyne, Kritiya Butthongkomvong, Marcos Pedro Guedes Camandaroba, Ke Cao, Marcela Carballido, Marcela Carballido, Jen‐Shi Chen, Ming‐Huang Chen, Ming-Huang Chen, Ashley Cheng, Tai‐Jan Chiu, Hye Jin Choi, Hong Jae Chon, Joëlle Collignon, Antonio Cubillo Gracián, S. Lindsey Davis, Ricardo Saraiva de Carvalho, D.J.A. de Groot, Anne Demols, Judith de Vos, Maria Diab, Jacob C. Easaw, Martin Eatock, Julien Edeline, Rawad Elias, Fredericus Eskens, Alfredo Falcone, Plinio Fernández, Richard S. Finn, Fábio Franke, Masayuki Furukawa, Junji Furuse, Olumide B. Gbolahan, Karen Geboes, Keri-Lee Geneser, Zhimin Geng, Ravit Geva, Roopinder Gillmore, Thorsten Oliver Goetze, Hongfeng Gou, Julieta Grasselli, Shanzhi Gu, Mahmut Gümüş, Nadia Haj Mohammad, Chunyi Hao, Hakan Harputluoğlu, Hassan Hatoum, Volker Heinemann, Wang Kwong Ho, Chiun Hsu, Ayala Hubert, Jun‐Eul Hwang, Mevlüde İnanç, Soledad Iseas, Vaishnavi Jeyasingam, Paula Jiménez Fonseca, Warren Joubert, Jitlada Juengsamarn and 116 more - The Lancet 2023 cited by 1,025

  6. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

    Authors: Richard S. Finn, Baek‐Yeol Ryoo, Philippe Merle, Masatoshi Kudo, Mohamed Bouattour, Ho Yeong Lim, В. В. Бредер, Julien Edeline, Yee Chao, Sadahisa Ogasawara, Thomas Yau, Marcelo Garrido, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Scot Ebbinghaus, Erluo Chen, Abby B. Siegel, Andrew X. Zhu, Ann‐Lii Cheng, on behalf of the KEYNOTE-240 investigators - Journal of Clinical Oncology 2019 cited by 1,819

  7. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma

    Authors: Andrew X. Zhu, Alexander R. Abbas, Marina Ruiz de Galarreta, Yinghui Guan, Shan Lu, Hartmut Koeppen, Wenjun Zhang, Chih‐Hung Hsu, Aiwu Ruth He, Baek‐Yeol Ryoo, Thomas Yau, Ahmed O. Kaseb, Adam M. Burgoyne, Farshid Dayyani, Jessica Spahn, Wendy Verret, Richard S. Finn, Han Chong Toh, Amaia Lujambio, Yulei Wang - Nature Medicine 2022 cited by 627

  8. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial

    Authors: Robin Kate Kelley, Lorenza Rimassa, Ann‐Lii Cheng, Ahmed O. Kaseb, Shukui Qin, Andrew X. Zhu, Stephen L. Chan, Tamar Melkadze, Wattana Sukeepaisarnjaroen, В. В. Бредер, Gontran Verset, Edward Gane, Ivan Borbath, Jose David Gomez Rangel, Baek‐Yeol Ryoo, Tamta Makharadze, Philippe Merle, Fawzi Benzaghou, Kamalika Banerjee, Saswati Hazra, Jonathan Fawcett, Thomas Yau - The Lancet Oncology 2022 cited by 522

  9. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

    Authors: B. Sangro, Stephen L. Chan, Robin Kate Kelley, George Lau, Masatoshi Kudo, Wattana Sukeepaisarnjaroen, M. Yarchoan, Enrico N. De Toni, J. Furuse, Yoon‐Koo Kang, Peter R. Galle, Lorenza Rimassa, Alexandra Heurgué, Vincent C. Tam, Tu Van Dao, S.C. Thungappa, В. В. Бредер, Y. Ostapenko, María Reig, M. Makowsky, Michael J. Paskow, Charu Gupta, John F. Kurland, Alejandra Negro, Ghassan K. Abou‐Alfa, Sérgio Santos de Azevêdo, Maria Ignez Braghiroli, Gustavo Girotto, Arinilda Campos Bragagnoli, Ricardo Branco, Adilson Faccio, Andrea Moretto, Nils Gunnar Skare, Jamille Dutra, Luciana Viola, Karina Vianna, Fernando Meton, Cláudia Vaz de Melo Sette, Amanda Faulhaber, Vincent C. Tam, Félix Couture, Jim Biagi, Hélène Castel, Karen Mulder, Yoo‐Joung Ko, Kevin Zbuk, Stephen Welch, Annie Beaudoin, Alexandra Heurgué, Éric Assenat, Isabelle Archambeaud, David Tougeron, Jean‐Marie Péron, Marine Gilabert, Jean–Pierre Bronowicki, Stéphane Cattan, Jean‐Frédéric Blanc, Mohamed Bouattour, Jean–Marc Phelip, Valérie Boige, Pierre Michel, Anne-Claire Frin, Enrico N. De Toni, Marie‐Luise Berres, Arndt Vogel, Thomas Berg, Thomas J. Ettrich, Dirk Waldschmidt, H. Wedemeyer, Marcus‐Alexander Wörns, Michael Bitzer, Karl-Heinz Weiss, George Lau, Stephen L. Chan, Thomas Yau, Y. Tai, Ann Shing Lee, Satheesh Chiradoni Thungappa, Lokesh K. N, Vikas Sureshchand Ostwal, Kattimani Kiran Ashok, Sushant Mittal, Hari Om Goyal, Sankar Srinivasan, Ghanashyam Biswas, Mallavarapu Mohan, Sewanti Limaye, Nirav Asarawala, Lorenza Rimassa, Alfredo Falcone, Luca Gianni, Antonio Gasbarrini, Bruno Daniele, Antonio Avallone, Giovanni Luca Frassineti, Fausto Roila, Masatoshi Kudo, Tomokazu Kawaoka, Manabu Morimoto, Yasuhiro Takikawa and 103 more - Annals of Oncology 2024 cited by 312

  10. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

    Authors: Robin Kate Kelley, Bruno Sangro, William Proctor Harris, Masafumi Ikeda, Takuji Okusaka, Yoon‐Koo Kang, Shukui Qin, David Tai, Ho Yeong Lim, Thomas Yau, Wei Peng Yong, Ann‐Lii Cheng, Antonio Gasbarrini, Silvia Damian, Jordi Bruix, Mitesh J. Borad, Johanna C. Bendell, Tae‐You Kim, Nathan Standifer, Philip He, Mallory Makowsky, Alejandra Negro, Masatoshi Kudo, Ghassan K. Abou‐Alfa - Journal of Clinical Oncology 2021 cited by 438

  11. Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

    Authors: Cristina Saura, Mafalda Oliveira, Yin‐Hsun Feng, Ming‐Shen Dai, Shang-Wen Chen, Sara A. Hurvitz, Sung‐Bae Kim, Beverly Moy, Suzette Delaloge, William J. Gradishar, Norikazu Masuda, Markéta Palácová, Maureen Trudeau, Johanna Mattson, Yoon Sim Yap, Ming‐Feng Hou, Michelino De Laurentiis, Yu‐Min Yeh, Hong‐Tai Chang, Thomas Yau, Hans Wildiers, Barbara Haley, Daniele Fagnani, Yen‐Shen Lu, John Crown, Johnson Lin, Masato Takahashi, Toshimi Takano, Miki Yamaguchi, Takaaki Fujii, Bin Yao, Judith D. Bebchuk, Kiana Keyvanjah, Richard Bryce, Adam Brufsky, for the NALA Investigators - Journal of Clinical Oncology 2020 cited by 609

  12. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

    Authors: Bruno Sangro, Ignacio Melero, Samir Wadhawan, Richard S. Finn, Ghassan K. Abou‐Alfa, Ann‐Lii Cheng, Thomas Yau, Junji Furuse, Joong‐Won Park, Zachary Boyd, Hao Tang, Yun Shen, Marina Tschaika, Jaclyn Neely, Anthony B. El-Khoueiry - Journal of Hepatology 2020 cited by 421

  13. Pembrolizumab (Keytruda)

    Authors: Gerry Gin Wai Kwok, Thomas Yau, Joanne Wing Yan Chiu, Eric Tse, Yok‐Lam Kwong - Human Vaccines & Immunotherapeutics 2016 cited by 481

  14. Systematic review and meta‐analysis of protein intake to support muscle mass and function in healthy adults

    Authors: Everson Araújo Nunes, Lauren M. Colenso‐Semple, Sean McKellar, Thomas Yau, Muhammad Usman Ali, Donna Fitzpatrick‐Lewis, Diana Sherifali, Claire Gaudichon, Daniel Tomé, Philip J. Atherton, Maria Camprubi Robles, Sandra Naranjo‐Modad, Michelle Braun, Francesco Landi, Stuart M. Phillips - Journal of Cachexia Sarcopenia and Muscle 2022 cited by 240

  15. Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.

    Authors: Peter R. Galle, Thomas Decaens, Masatoshi Kudo, Shukui Qin, Leonardo Fonseca, Bruno Sangro, Hatim Karachiwala, Joong‐Won Park, Edward Gane, Matthias Pinter, David Tai, Armando Santoro, Gonzalo Pizarro, Chang‐Fang Chiu, Michael Schenker, Aiwu Ruth He, Qi Wang, Caitlyn Stromko, Joseph Hreiki, Thomas Yau - Journal of Clinical Oncology 2024 cited by 146

  16. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: Jin Li, Shukui Qin, Rui‐Hua Xu, Thomas Yau, Brigette Ma, Hongming Pan, Jianming Xu, Yuxian Bai, Yihebali Chi, Liwei Wang, Kun‐Huei Yeh, Feng Bi, Ying Cheng, Anh T. Le, Jen-Kou Lin, Tianshu Liu, Dong Ma, Christian Kappeler, J. Kalmus, Tae Won Kim - The Lancet Oncology 2015 cited by 816

  17. Adjuvant nab -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

    Authors: Margaret A. Tempero, Uwe Pelzer, Eileen M. O’Reilly, Jordan M. Winter, Do‐Youn Oh, Chung‐Pin Li, Giampaolo Tortora, Heung-Moon Chang, Charles D. Lopez, Tanios Bekaii‐Saab, Andrew H. Ko, Armando Santoro, Joon Oh Park, Marcus Smith Noel, Giovanni Luca Frassineti, Yan‐Shen Shan, Andrew Dean, Hanno Riess, Eric Van Cutsem, Jordan Berlin, Philip Philip, Malcolm J. Moore, David Goldstein, Josep Tabernero, Mingyu Li, Stefano Ferrara, Yvan Le Bruchec, George Zhang, Brian Lu, Andrew V. Biankin, Michele Reni, Richard A. Epstein, Paul L. Vasey, Jeremy Shapiro, Matthew Burge, Yu Jo Chua, Marion Harris, Nick Pavlakis, Niall C. Tebbutt, Gerald W. Prager, Christian Dittrich, Friedrich Längle, Kathrin Philipp‐Abbrederis, Richard Greil, Herbert Stöger, Michael Girschikofsky, Thomas Kuehr, Jean–Luc Van Laethem, Stéphanie Laurent, Neesha C. Dhani, Yoo Joung Ko, Scot Dowden, Petr Kavan, Mustapha Édouard Tehfe, Eugen Kubala, Milan Kohoutek, Per Pfeiffer, Mette Yilmaz, Vibeke K. Parner, Tapio Salminen, Leena‐Maija Soveri, Eija Korkeila, Pia Österlund, Julien Taı̈eb, David Tougeron, Pascal Artru, François‐Xavier Caroli‐Bosc, Rosine Guimbaud, Antony Turpin, Thomas Walter, Jean‐Baptiste Bachet, Volker Kunzmann, Florian Kreth, Andreas De Block, Marino Venerito, Helmut Oettle, Meinolf Karthaus, Jörg Trojan, Gunnar Folprecht, Markus M. Lerch, Frank Kullmann, Marcel Reiser, Volker Heinemann, Marcus‐Alexander Wörns, H. Schulz, Benjamin Garlipp, Thomas Yau, Lam Stephen Chan, Balázs Juhász, László Landherr, Tamás Pintér, G. Bodoky, Zsuzsanna Kahán, Raymond McDermott, Derek G. Power, Luca Gianni, Salvatore Siena, Michèle Milella, Alfredo Falcone, Rossana Berardi and 87 more - Journal of Clinical Oncology 2022 cited by 132

  18. First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma

    Authors: Richard D. Kim, Debashis Sarker, Tim Meyer, Thomas Yau, Teresa Macarulla, Joong‐Won Park, Su Pin Choo, Antoine Hollebecque, Max W. Sung, Ho-Yeong Lim, Vincenzo Mazzaferro, Joerg Trojan, Andrew X. Zhu, Jung‐Hwan Yoon, Sunil Sharma, Zhong-Zhe Lin, Stephen L. Chan, Sandrine Faivre, Lynn G. Feun, Chia-Jui Yen, Jean‐François Dufour, Daniel H. Palmer, Josep M. Llovet, Melissa Manoogian, Meera Tugnait, Nicolas Stransky, Margit Hagel, Nancy E. Kohl, Christoph Lengauer, Cori Ann Sherwin, Oleg Schmidt‐Kittler, Klaus P. Hoeflich, Hongliang Shi, Beni B. Wolf, Yoon‐Koo Kang - Cancer Discovery 2019 cited by 250

  19. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice

    Authors: David Kung‐Chun Chiu, Vincent Wai‐Hin Yuen, Jacinth Wing‐Sum Cheu, Larry Lai Wei, Vox Ting, Michael Fehlings, Hermi Sumatoh, Alessandra Nardin, Evan W. Newell, Irene Oi‐Lin Ng, Thomas Yau, Chun‐Ming Wong, Carmen Chak‐Lui Wong - Gastroenterology 2020 cited by 165

  20. Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib

    Authors: Masatoshi Kudo, Richard S. Finn, Julien Edeline, Stéphane Cattan, Sadahisa Ogasawara, Daniel H. Palmer, Chris Verslype, Vittorina Zagonel, Lætitia Fartoux, Arndt Vogel, Debashis Sarker, Gontran Verset, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Thomas Yau, Ellen B. Gurary, Abby B. Siegel, Anran Wang, Ann‐Lii Cheng, Andrew X. Zhu - European Journal of Cancer 2022 cited by 129

  21. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors

    Authors: Jeffrey Sum Lung Wong, Gerry Gin Wai Kwok, Vikki Tang, Bryan Cho Wing Li, Roland Leung, Joanne Wing Yan Chiu, Ka Wing, Wong Hoi She, Josephine Tsang, Chung Mau Lo, Tan To Cheung, Thomas Yau - Journal for ImmunoTherapy of Cancer 2021 cited by 132

  22. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study

    Authors: Thomas Yau, Ahmed O. Kaseb, Ann‐Lii Cheng, Shukui Qin, Andrew X. Zhu, Stephen L. Chan, Tamar Melkadze, Wattana Sukeepaisarnjaroen, Valery Breder, Gontran Verset, Edward Gane, Ivan Borbath, Jose David Gomez Rangel, Baek‐Yeol Ryoo, Tamta Makharadze, Philippe Merle, Fawzi Benzaghou, Steven Milwee, Zhong Wang, Dominic Curran, Robin Kate Kelley, Lorenza Rimassa - ˜The œLancet. Gastroenterology & hepatology 2024 cited by 82

  23. CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

    Authors: Thomas Yau, J.W. Park, Richard S. Finn, Ann‐Lii Cheng, Philippe Mathurin, Julien Edeline, Masatoshi Kudo, Kwang‐Hyub Han, James J. Harding, Philippe Merle, Olivier Rosmorduc, Lucjan Wyrwicz, E. Schott, Su Pin Choo, Robin Kate Kelley, Damir Begic, G. Chen, Jaclyn Neely, Jeffrey Anderson, Bruno Sangro - Annals of Oncology 2019 cited by 648

  24. Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study

    Authors: Shukui Qin, Zhenggang Ren, Yin‐Hsun Feng, Thomas Yau, Baocheng Wang, Haitao Zhao, Yuxian Bai, Shanzhi Gu, Lindong Li, Sairy Hernandez, Derek-Zhen Xu, Sohail Mulla, Yifan Wang, Hui Shao, Ann‐Lii Cheng - Liver Cancer 2021 cited by 129